Browse All

Current Filters

CLEAR FILTER x

TITLE

Long-term Safety and Efficacy of Zilucoplan in Myasthenia Gravis: Additional Interim Analyses of RAISE-XT

Author:Howard, James F.   Freimer, Miriam   Genge, Angela   Hewamadduma, Channa   Hussain, Yessar   Maniaol, Angelina   Mantegazza, Renato   Smilowski, Marek   Utsugisawa, Kimiaki   Vu, Tuan   Weiss, Michael   Duda, Petra   Boroojerdi, Babak   Vanderkelen, Mark   De La Borderie, Guillemette   Leite, M. Isabel   

Session Name:S15: Autoimmune Neuromuscular Diseases: New Observations and Therapeutic Approaches  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S15.002  

Author Institution:Department of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, Chapel Hill, NC  Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA, Columbus, OH  Clinical Research Unit, The Montreal Neurological Institute, Montreal, QC, Canada, Montreal, QC, Canada  Academic Neuroscience Unit, Sheffield Teaching Hospitals Foundation Trust, Sheffield, UK  Sheffield Institute for Translational Neurosciences (SITRAN), University of Sheffield, Sheffield, UK, Sheffield, United Kingdom  Department of Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA, Austin, TX  Department of Neurology, Oslo University Hospital, Oslo, Norway, Oslo, Norway  Department of Neuroimmunology and Neuromuscular Diseases, Fondazione IRCCS, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy, Milan, Italy  Medical University of Silesia, Katowice, Poland, KATOWICE, Poland  Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan, Hanamaki, Japan  Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA, Tampa, FL  Department of Neurology, University of Washington Medical Center, Seattle, WA, USA, Seattle, WA  UCB Pharma, Cambridge, MA, USA, Cambridge, MA  UCB Pharma, Monheim, Germany, Monheim, Germany  UCB Pharma, Braine-l’Alleud, Belgium, Braine L'Alleud, Belgium  UCB Pharma, Brussels, Belgium, Brussels, Belgium  Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK , Oxford, United Kingdom  

Long-term Efficacy and Safety of Ravulizumab, a Long-acting Terminal Complement Inhibitor, in Adults with Anti-acetylcholine Receptor Antibody-positive Generalized Myasthenia Gravis: Final Results from the Phase 3 CHAMPION MG Open-label Extension

Author:Vu, Tuan   Mantegazza, Renato   Annane, Djillali   Katsuno, Masahisa   Meisel, Andreas   Nicolle, Michael   Bril, Vera   Aguzzi, Rasha   Frick, Glen   Howard, James   

Session Name:S15: Autoimmune Neuromuscular Diseases: New Observations and Therapeutic Approaches  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S15.010  

Author Institution:University of South Florida Morsani College of Medicine, Tampa, FL  Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy  Hôpital Raymond Poincaré, Garches, France  Nagoya University Graduate School of Medicine, Nagoya, Japan  Charité Universitätsmedizin Berlin, Berlin, Germany  London Health Sciences Centre, London, ON, Canada  University of Toronto, Toronto, ON, Canada  Alexion, AstraZeneca Rare Disease, Boston, MA  The University of North Carolina, Chapel Hill, NC  

Clinically Meaningful Improvement in Physical Fatigue and Muscle Weakness Fatigability with Rozanolixizumab: Post-hoc Analysis of MG Symptoms PRO Responder Rate in the MycarinG study

Author:Habib, Ali A.   Kaminski, Henry J.   Grosskreutz, Julian   Mantegazza, Renato   Vu, Tuan   Vissing, John   Boehnlein, Marion   Greve, Bernhard   Grimson, Fiona   Hareendran, Asha   Bril, Vera   

Session Name:P4: Neuromuscular and Clinical Neurophysiology (EMG): Myasthenia Gravis 1  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:P4.001  

Author Institution:MDA ALS and Neuromuscular Center, University of California, Irvine, Irvine, CA, USA, Orange, CA  Department of Neurology & Rehabilitation Medicine, George Washington University, Washington, DC, USA, Washington, DC  Precision Neurology, Department of Neurology, University of Lübeck, Lübeck, Germany, Lübeck, Germany  Department of Neuroimmunology and Neuromuscular Diseases, Fondazione IRCCS, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy, Milan, Italy  Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA, Tampa, FL  Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, Copenhagen, Denmark  UCB Pharma, Monheim, Germany, Monheim, Germany  UCB Pharma, Slough, UK, London, United Kingdom  UCB Pharma, Slough, UK, Slough , United Kingdom  University Health Network, Toronto, ON, Canada, Toronto, ON, Canada  

The Safety and Efficacy of Chronic Weekly Rozanolixizumab Treatment in Patients with Generalized Myasthenia Gravis (MG0004)

Author:Bril, Vera   Druzdz, Artur   Grosskreutz, Julian   Habib, Ali A.   Kaminski, Henry J.   Mantegazza, Renato   Sacconi, Sabrina   Utsugisawa, Kimiaki   Vu, Tuan   Boehnlein, Marion   Woltering, Franz   Greve, Bernhard   Gayfieva, Maryam   Vissing, John   

Session Name:P4: Autoimmune Neurology: Peripheral Autoimmunity  

Topic:Autoimmune Neurology  

Program Number:P4.017  

Author Institution:University Health Network, Toronto, ON, Canada, Toronto, ON, Canada  Department of Neurology, Municipal Hospital, Poznan, Poland, Swarzedz, Poland  Precision Neurology, Department of Neurology, University of Lübeck, Lübeck, Germany, Lubeck, Germany  MDA ALS and Neuromuscular Center, University of California, Irvine, Irvine, CA, USA, Orange, CA  Department of Neurology & Rehabilitation Medicine, George Washington University, Washington, DC, USA, Washington, DC  Department of Neuroimmunology and Neuromuscular Diseases, Fondazione IRCCS, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy, Milan, Italy  Université Côte d’Azur, Peripheral Nervous System & Muscle Department, Pasteur 2 Hospital, Centre Hospitalier Universitaire de Nice, Nice, France, Nice, France  Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan, Hanamaki, Japan  Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA, Tampa, FL  UCB Pharma, Monheim, Germany, Monheim, Germany  UCB Pharma, Monheim, Germany, Monheim Am Rhein, Germany  UCB Pharma, Slough, UK, London, United Kingdom  Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, Copenhagen, Denmark  

Drivers of New Rozanolixizumab Treatment Cycles in Patients with Generalized Myasthenia Gravis in the Phase 3 MycarinG and Open-label Extension Studies

Author:Mahuwala, Zabeen K.   Grosskreutz, Julian   Habib, Ali A.   Mantegazza, Renato   Pascuzzi, Robert M.   Sacconi, Sabrina   Vissing, John   Vu, Tuan   Beau-Lejdstrom, Raphaelle   Greve, Bernhard   Grimson, Fiona   Tarancón, Thaïs   Bril, Vera   

Session Name:P10: Neuromuscular and Clinical Neurophysiology (EMG): Myasthenia Gravis 3  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:P10.003  

Author Institution:Department of Neuromuscular Medicine, Epilepsy and Clinical Neurophysiology, University of Kentucky, Lexington, KY, USA, LEXINGTON, KY  Precision Neurology, Department of Neurology, University of Lübeck, Lübeck, Germany, Lübeck, Germany  MDA ALS and Neuromuscular Center, University of California, Irvine, Irvine, CA, USA, Orange, CA  Department of Neuroimmunology and Neuromuscular Diseases, Fondazione IRCCS, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy, Milan, Italy  Neurology Department, Indiana University School of Medicine, Indiana University Health, Indianapolis, IN, USA, Indianapolis, IN  Université Côte d'Azur, Peripheral Nervous System & Muscle Department, Pasteur 2 Hospital, Centre Hospitalier Universitaire de Nice, Nice, France, Nice, France  Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, Copenhagen, Denmark  Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA, Tampa, FL  UCB Pharma, Bulle, Switzerland, Bulle, Switzerland  UCB Pharma, Monheim, Germany, Monheim, Germany  UCB Pharma, Slough, UK, London, United Kingdom  UCB Pharma, Madrid, Spain, Madrid, Spain  University Health Network, Toronto, ON, Canada, Toronto, ON, Canada